Dimensional Fund Advisors LP Decreases Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Dimensional Fund Advisors LP cut its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,907,066 shares of the company's stock after selling 51,952 shares during the period. Dimensional Fund Advisors LP owned 5.88% of Prestige Consumer Healthcare worth $227,011,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $42,593,000. Norges Bank acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,009,000. Bessemer Group Inc. lifted its stake in Prestige Consumer Healthcare by 10,053.1% in the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock valued at $23,041,000 after buying an additional 292,144 shares during the period. Boston Trust Walden Corp lifted its stake in Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock valued at $64,942,000 after buying an additional 252,089 shares during the period. Finally, Natixis Advisors LLC lifted its stake in Prestige Consumer Healthcare by 1,335.1% in the fourth quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after buying an additional 194,665 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded up $0.99 during mid-day trading on Friday, hitting $80.52. 270,919 shares of the stock traded hands, compared to its average volume of 287,807. The business's 50-day moving average price is $83.60 and its 200 day moving average price is $80.65. The company has a market cap of $3.99 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Royal Bank of Canada boosted their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday, March 21st. Canaccord Genuity Group boosted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Oppenheimer upped their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, April 8th. Finally, DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.